Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 75027, held by Padagis US. Clobetasol Propionate.
As of Nov 16, 2026, ANDA 75027 (Clobetasol Propionate), held by Padagis US, was first approved by FDA on Oct 31, 1997, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clobetasol Propionate Gel, 0.05% is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clobetasol Propionate0.05% · gel;topical | Clobetasol Propionate | Rx |
| Nov 28, 2007 | Supplement 5Labeling | Approved | None posted |
| Dec 20, 2000 | Supplement 3Manufacturing | Approved | None posted |
| Dec 20, 2000 | Supplement 4Labeling | Approved | None posted |
| Jul 24, 2000 | Supplement 2Labeling | Approved | None posted |
| Oct 31, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters